Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro (NYSE:NVRO) and Amag Pharmaceuticals (NASDAQ:AMAG).
Nevro (NVRO)
In a report released today, Joanne Wuensch from BMO Capital maintained a Buy rating on Nevro, with a price target of $76. The company’s shares closed on Friday at $58.94.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 12.4% and a 72.2% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and Wright Medical Group.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nevro with a $76.25 average price target, representing a 29.4% upside. In a report issued on July 25, Canaccord Genuity also maintained a Buy rating on the stock with a $80 price target.
.
See today’s analyst top recommended stocks >>
Amag Pharmaceuticals (AMAG)
Cantor Fitzgerald analyst William Tanner maintained a Hold rating on Amag Pharmaceuticals today and set a price target of $18. The company’s shares closed on Friday at $23.90, close to its 52-week high of $25.63.
According to TipRanks.com, Tanner is a 2-star analyst with an average return of 1.0% and a 43.2% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.
Currently, the analyst consensus on Amag Pharmaceuticals is a Hold with an average price target of $23.80, a -0.4% downside from current levels. In a report issued on August 2, Piper Jaffray also maintained a Hold rating on the stock with a $22 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
